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Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with limited
therapeutic options. Since HCC has been shown to be immunogenic, immunotherapy is considered a promising
therapeutic approach. Small interfering RNAs (siRNAs), depending on their structure and sequence, can trigger
the innate immune system, which can potentially enhance the adaptive anticancer immune response in the
tumor-bearing subjects. Immunostimulatory properties of nucleic acids can be applied to develop adjuvants for
HCC treatment.
Methods: The transplantable HCC G-29 tumor in male CBA/LacSto (CBA) mice was used to study the effects of
immunostimulatory RNA on tumor growth. Tumor size, metastases area in different organs of mice and mouse
survival rate were analyzed. Furthermore the mouse serum IFN-α levels were measured using ELISA.
Results: In the present study, we found that a 19-bp RNA duplex (ImmunoStimulattory RNA or isRNA) with 3-nt
overhangs at the 3′-ends of specific sequence displays immunostimulatory, antitumor, and antimetastatic activities
in mice bearing HCC G-29. Our results demonstrate that isRNA strongly increases the level of interferon-α (IFN-α) by
up to 25-fold relative to the level in mice injected with Lipofectamine alone (Mock), and to a lesser extent increases
the level of proinflammatory cytokine interleukin-6 (IL-6) (by up to 5.5-fold relative to the Mock level), in mice blood
serum. We showed that isRNA reliably (P < 0.05) inhibits primary tumor growth in mice compared to the mock
group. Furthermore, injections of isRNA significantly enhanced necrotic processes in the center of the primary
tumor, and decreased by twofold the width of the undifferentiated peripheral zone and the number of mitotic cells
in this zone. The results showed that isRNA efficiently reduces the area of metastases in the liver, kidneys, and heart
of CBA/LacSto mice with HCC.
Conclusions: The obtained results clearly demonstrate immunostimulatory and antimetastatic properties of the
isRNAs in mice with HCC. Consequently, this short double-stranded RNA can be considered as a potential adjuvant
for the therapy of HCC.
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Hepatocellular carcinoma (HCC) is one of the most
common cancers and the third leading cause of cancer-
related deaths worldwide [1]. The standard methods of
hepatocarcinoma treatment include surgical resection,
chemical therapy, radiotherapy, ultrasound ablation, or
liver transplantation [2-5]. However, the high rate of* Correspondence: elena_ch@niboch.nsc.ru
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unless otherwise stated.recurrence after these therapeutic procedures remains a
big issue in patients with HCC. In view of these facts,
the necessity to use adjuvant therapy becomes urgent.
Tumor pathogenesis is accompanied by disorders of the
immune system, leading to the escape of the tumor from
the immune response. At the same time, the immune
status of an organism is impaired, and immunodeficiency
is developed. Immunotherapy aims to provide a more
efficient targeting of tumor cells by inducing or boos-
ting the existing tumor-specific immune response.
Immunostimulatory agents are widely used as a part ofl Ltd. This is an Open Access article distributed under the terms of the Creative
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ment of different cancers [6-9]. Moreover, HCC patients
with tumors containing infiltrated tumor-specific effector
T cells have a reduced risk of tumor recurrence following
liver transplantation [10]. The following methods of adju-
vant therapy were proposed for the treatment of HCC
patients: cellular immunotherapy [11], interferon (IFN)
therapy [12], and therapy using endogenous IFN inducers
[13]. It should be noted that in many cases, HCC de-
velops on a background of chronic inflammatory liver
disease such as hepatitis B and C or cirrhosis. Many
studies have documented that IFN therapy significantly
suppresses the onset of HCC from chronic hepatitis and
liver cirrhosis [14-16].
Natural and synthetic immunostimulators cause a wide
variety of effects at the levels of the immunocompetent
cells and an entire organism including activation of
different types of immune cells (macrophages, T- and
B-lymphocytes, NK-cells), induction of type I interferons
and/or inflammatory cytokines synthesis by immune cells,
and also cause proliferation blockage, and differentiation
or apoptosis of tumor cells. The innate immune system
can be activated by exogenous nucleic acids (e.g., bacterial,
viral, and fungal nucleic acids) via several families of pat-
tern recognition receptors, including endosomal Toll-like
receptors (TLRs) 3/7/8/9 or cytosolic receptors: retinoic
acid inducible gene-I (RIG-I)-like helicases including
RIG1 and melanoma differentiation-associated gene 5
(MDA5); Interferon-induced, double-stranded RNA-acti-
vated protein kinase (PKR); 2′-5′-oligoadenylate synthase
1 and 2 (OAS); and less studied NOD-like receptors
(NLRP3, NOD2) [17,18]. These receptors are responsible
for the activation of the complement system, coagulation,
opsonization, phagocytosis, and the induction of apoptosis
and cytokine production. The role of TLRs in antitumor
protection of an organism is confirmed by the fact that
mutations in the genes encoding TLRs increase both the
incidence of infectious diseases and the frequency of can-
cer [19]. The antitumor activity of TLR 3/7/8/9 agonists
has been demonstrated in several tumor types including
melanoma, breast cancer, renal cell carcinoma, glioblast-
oma, cutaneous T-cell and non-Hodgkin’s lymphomas,
and basal cell carcinoma [6]. Unlike other cancers, the
treatment of HCC involves not only the treatment of the
carcinoma itself, but also the treatment of underlying
chronic hepatitis. TLR7 and −9 agonists have great the-
rapeutic potential against HCC because they induce the
synthesis of the mediators of anti-viral and anticancer
immunity such as IFN-α and IFN-γ-inducible protein 10
(IP-10), and induce a sustained increase in 2′5′-oligoade-
nylate synthesis [20]. In a recent phase 1 trial in patients
with chronic HCV infection, TLR7 agonist isatoribine
(Anadys Pharmaceuticals, Inc.) and TLR9 ligand CPG
10101 (Actilon; Coley Pharmaceutical Group, Inc.) inducedan effective decrease in HCV RNA [13,21-23] and the
anti-viral effect was similar to that reported for pegy-
lated interferon monotherapy [23].
Recently, we designed a series of short double-stranded
RNAs that possess pronounced antiproliferative activity in
cancer cells [24,25]. The study of their sequence/activity
relationships showed [25] that the introduction of substi-
tutions in the middle part of isRNA sequence does not
alter the antiproliferative activity. Disruption of GUGU
motif at the 5′-end of strand 1, which is similar to the re-
duced version of immunostimulatory sequence according
to [26], caused a minor decrease of the antiproliferative
activity compared with the parent isRNA. While substitu-
tions in the 3′-end regions of isRNA substantially reduce
its biological activity. Thus, introduction of only one sub-
stitution, disrupting oligoU6 motif at the 3′-end of strand
1 entirely abolishes the antiproliferative activity. The
sequence of these molecules did not have substantial
homology to any human or mouse mRNAs, and these
compounds were shown to have the immunostimulatory
effects in culture of human adherent peripheral blood
mononuclear cells (PBMCs) and in C57BL mice.
In this study we investigated the antitumor and anti-
metastatic properties of the selected most effective im-
munostimulatory RNA (isRNA) in CBA/LacSto mice
with hepatocellular carcinoma G-29. We show that the
isRNA induces interferon-α production in mice, inhibits
tumor growth, and efficiently reduces the metastases




Oligoribonucleotides (strand 1: 5′-AAAUCUGAAAGC
CUGACACUUA-3′ and strand 2: 5′-GUGUCAGGCU
UUCAGAUUUUUU-3′) were synthesized on an auto-
matic ASM-800 DNA/RNA synthesizer (Biosset) using
ribo-β-cyanoethyl phosphoramidites (Glen Research). After
standard deprotection, oligoribonucleotides were puri-
fied using denaturing polyacrylamide gel electrophoresis
(PAGE) and were then isolated as sodium salts. Oligori-
bonucleotides were characterized by MALDI-TOF mass
spectra on REFLEX III (Bruker Daltonics, Germany).
isRNAs were annealed at a concentration of 50 μM in a
buffer containing 30 mM HEPES-KOH (pH 7.4), 100 mM
sodium acetate, and 2 mM magnesium acetate.
High purity polyinosinic-polycytidylic acid (poly(I:C))
(less than 1% free nucleotides) was purchased from
Sigma-Aldrich.
Mice and injection of isRNAs
All animal procedures were carried out in accordance with
the protocols approved by the Bio-ethics committee of the
Siberian Branch of the Russian Academy of Sciences and
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animals (European Communities Council Directive 86/
609/CEE). We used male CBA/LacSto (CBA) mice from
vivarium of the Institute of Cytology and Genetics SB
RAS. Mice were 10–14 weeks old at the beginning of the
experiments with an average weight of 23–27 g. Mice
were housed in groups of 8–10 individuals in plastic cages,
and had free access to food and water; daylight conditions
were normal.
isRNA and poly(I:C) were complexed with Lipofecta-
mine 2000 (Invitrogene) according to the manufacturer’s
protocol. Briefly, 10 μg per mouse of isRNA or poly(I:C)
was mixed with 35 μl of Lipofectamine in 200 μl of
OptiMEM medium and incubated at room temperature
for 20 min, and then the preparation was injected intra-
peritoneally or intravenously into mice.Analysis of IFN-α and IL-6 levels in mouse blood serum
10–14-week-old male CBA mice were injected intraperito-
neally with 200 μl of isRNA/Lipofectamine complexes in
sterile OptiMEM medium and the blood was collected 1,
6, 10 or 16 hours after the injection via head-clipping. The
serum was prepared from the whole blood by coagulation
for 30 min at 37°C and subsequent centrifugation, and
the levels of IFN-α and IL-6 were measured using sand-
wich ELISA kits (BD Biosciences) in accordance with the
manufacturer’s instructions. Samples were measured in
triplicate.Tumor treatment
Transplantable Hepatocarcinoma-29 (G-29) tumor was
used throughout these experiments. It is maintained in
the vivarium of ICG SB RAS by regular passages in CBA
mice. The solid form of the tumor was used in these
experiments. 2 × 105 tumor cells in a volume of 100 μl
were transplanted into the right thigh muscles of 40
male CBA mice. After tumor transplantation, the ani-
mals were divided into experimental and control groups
and then were kept in their compartments until the end
of the experiment. For tumor treatment, on days 2, 5, 8,
and 12 after tumor transplantation, mice received intra-
peritoneal injections of isRNA/Lipofectamine complexes
in sterile OptiMEM. Control mice were injected with
the same volumes of vehicle. Tumor volume was mea-
sured with calipers and calculated using the formula
π/6 × (length × width × height). On the 24th day after
tumor inoculation, three mice from each group were
taken out of the experiment by dislocation of cervical
vertebrae. The organs of mice and the primary tumors
were fixed in 4% formaldehyde solution in DMEM, and
processed for paraffin sectioning by standard protocols.
The remaining tumor-bearing mice were kept for the
study of the survival rate.Microscopy
Paraffin cross-sections of the primary tumor were
stained with hematoxylin/eosin and with the Mallory
staining according to standard protocols. Images were
obtained using a microscope DM2500 equipped with a
digital camera DFC420 (Leica, Germany). The percent-
age of the metastases area was determined relative to
the total area of sections using Adobe Photoshop Soft-
ware from five random fields of view (magnification of
lens 10×), and the confidence interval with parameter
α = 0.05. Metastases in the heart had a strongly elon-
gated shape that did not allow applying this method for
the evaluation of their relative area. The area of metasta-
ses in the heart was determined using the following for-
mula: X = (20 × l × n/106) × 100, where the average width
of the metastasis in mice hearts from all groups was ob-
tained from direct measurements and set as 20 μm. l
and n were the average length and number of metastases
per mm2 of cross section of the mice heart in each
group, respectively.
Statistics
The statistical significance of the differences in IFN-α pro-
duction was determined using the two-tailed Student’s
t-test (data are expressed as means ± SD). The nonpara-
metric Mann–Whitney U test was used for the analysis
of the tumor size and metastases area to compare the
mean values between two groups (data are expressed as
means ± SEM). Differences were considered statistically
significant for p < 0.05.
Results
Cytokine induction by isRNAs in mice
In the present study we used the most effective among
previously tested [25] immunostimulatory isRNA mole-
cules of 19-bp long with 3-nt overhangs at the 3′-ends.
As the positive control, poly(I:C), which is known to in-
duce an interferon response, was used [27].
The levels of IFN-α and IL-6 in mouse blood serum
after intraperitoneal administration of isRNA or poly(I:C)
in CBA/LacSto mice were assayed to determine the
immunostimulatory potential of isRNA. Groups of mice
were injected with isRNA or poly(I:C) (10 μg per mouse)
complexed with Lipofectamine, or with Lipofectamine
only. The blood samples were collected 1, 6, 10, and
16 hours post-injection to measure the levels of IFN-α
and IL-6. The results reveal (Figure 1) that both isRNA
and poly(I:C), induce IFN-α and IL-6 secretion in mouse
blood serum. isRNA induces 15-fold increase of IFN-α
level in serum 10 hours after injection (Figure 1A), and
the maximum level of IFN-α synthesis was observed
16 hours after injection, up to a 25-fold increase relative
to the level in the mice injected with Lipofectamine
(“Mock”). A different time-course was observed for
Figure 1 Stimulation of the innate immune response by isRNA and poly(I:C) in vivo. СBA/LacSto mice were intraperitoneally injected with
isRNA (10 μg per mouse) or poly(I:C) (10 μg per mouse) in complex with Lipofectamine 2000. Serum IFN-a (A) and IL-6 (B) levels were measured
by ELISA 6 h 1, 6, 10, and 16 hours after injection. Values for Lipofectamine-treated mice represent the Mock. The data represent means ± standard
deviation (SD) calculated from measurements from at least three mice.
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served 6 – 10 hours post-injection and reached the level
2.2-fold higher than that for isRNA. The time-courses of
the activation of IL-6 synthesis (Figure 1B) were also dif-
ferent for isRNA and poly(I:C). Thus, the isRNA induces
2.5 - 4.5-fold increase of IL-6 level relative to the level in
Mock-treated mice 1 – 6 hours after injection, and
reached the initial level by 10 h. The poly(I:C) induces
more strong and prolonged increase of IL-6 level up
to ~17-fold relative to the level in Mock-treated mice, 6 –
16 hours post-injection. Injections of Lipofectamine
(“Mock”) without isRNA also induced a ~2-fold increase
of IL-6 level 1–6 hours post-injection.Antitumor effect of isRNA
Antitumor and antimetastatic properties of isRNAs were
investigated in the model of HCC G-29 tumor that is
accompanied by the formation of multiple metastases in
different organs of mice [28]. The experiments were per-
formed according to the following scheme: G-29 cells
(200,000 cells/mouse) were intramuscularly injected in
the right thigh of mice. The intraperitoneal injections of
isRNA or poly(I:C) complexed with Lipofectamine, as
well as mock injections (Lipofectamine 2000), were per-
formed at days 2, 5, 8, and 12 after tumor implantation.
During the experiments, the size of the primary tumors
was monitored each day. Data displayed in Figure 2
Figure 2 Influence of isRNA injections on HCC primary tumor growth. CBA/LacSto mice were intramuscularly injected with G-29 cells and
treated with isRNA or poly(I:C) i.p. injections. The data represent means ± standard error of the mean (SEM) at day 22 (n = 8–10). P≤ 0.05 according to
Mann–Whitney test.
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inhibition of HCC G-29 tumor growth in comparison
with the mock-treated group of mice. However, the
difference in tumor size between isRNA-treated and un-
treated animals was not statistically relevant. It should be
noted that in the group of mice treated with poly(I:C), the
average tumor size was comparable with the tumor size in
the untreated animals.
Since the primary tumor is the source of HCC cells
metastasizing to other organs, it was interesting to study
the influence of isRNA treatment on the morphology of
the primary tumors. Paraffin sections of primary tumors
were prepared according to standard protocols and
studied by light microscopy. The primary tumor under a
connective tissue capsule was composed of two distinct
zones formed by different cellular elements: peripheral
(Figure 3A, B) and central (Figure 3C, D). The peripheral
zone was located under the skin and contained elon-
gated cells (8–10 μm) with a large nucleus occupying
most of the cell, and a light cytoplasm. The boundaries
of the cells were fuzzy. These cells actively divided, and
a large number of mitoses were seen in the sections. The
peripheral zone of the primary tumor was characterized
by good vascularization and a small intercellular space
(Figure 3A, B). Presumably, from this area, cells entered
the bloodstream and subsequently developed metastases
in the visceral organs. The central zone had lower
vascularization and cells were arranged in bundles of
3–5 cells separated by thin layers of connective tissue.
Mitoses were absent. The cells in this zone were larger
(>10 μm), and round-shaped with a round nucleus sur-
rounded by eosinophilic cytoplasm. Binuclear cells wereoften found, and sometimes there were multinucleated
cells. The boundaries of the cells were clearly distin-
guishable, and widened intercellular spaces were seen
along many apoptotic cells and necrotic foci (Figure 3C,
D).
Morphometric analysis of primary tumor cross-sections
demonstrated that isRNA treatment caused a more than
twofold decrease of the width of the peripheral zone in
comparison with those in untreated or mock-treated mice.
Thus, the average width of the peripheral zone in isRNA-
treated mice was 400 μm (Figure 3B) versus 800–900 μm
for control mice (Figure 3A) and 700–4000 μm for mock-
treated mice. In the peripheral zone of mice injected with
isRNA, the number of mitoses was reduced in comparison
with the mice from control groups from 15 to 8 per mm2
of cross sections. There were the large focal necroses that
formed several large cavities in the central zone of primary
tumors of isRNA-treated mice (Figure 3D), while in other
groups the cavities were much smaller (Figure 3C). It
should be noted that injections of poly(I:C) also caused a
more than twofold decrease in the number of dividing
cells (to 6.5 per mm2 of sections) in the peripheral zone of
the primary tumor. However, the width of the peripheral
zone of tumor in poly(I:C)-treated mice was highly varied
(up to 1.5 mm).
To assess the therapeutic efficacy of isRNA monothe-
rapy, we compared the survival of the mice in different ex-
perimental groups. It was shown (Figure 4) that isRNA
treatment increased the survival time by 5% in comparison
with the mice from untreated and mock-treated groups.
Thus, in the control and mock-treated groups of mice, the
average life expectancy was 28.8 ± 0.6 and 28.2 ± 0.9,
Figure 3 Cross-sections of HCC G-29 primary tumors 22 days after tumor inoculation. Peripheral zone of primary tumor in untreated (A)
and isRNA-treated (B) mice: arrows show zone of undifferentiated cells. C, D - central area of primary tumor in untreated (C) and isRNA-treated
(D) mice: necrosis and foci of cell death are indicated by arrows. Paraffin sections, Mallory’s trichrome staining.
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mice, the average life expectancy was 29.7 ± 0.9 and 30 ±
1.6, respectively.
Antimetastatic effect of isRNA
Morphometric analysis to measure the average metas-
tases area relative to the total area in different visceral
organs was performed to evaluate antimetastatic effects
of isRNA in mice with HCC G-29. Morphology of me-
tastases in different organs of all mice visually did notFigure 4 The survival rate of mice after inoculation of HCC G-29 cellsdiffer (Figure 5), while the size and number of meta-
stases per mm2 of section in isRNA-treated mice signifi-
cantly decreased in comparison with control groups of
mice and poly(I:C)-treated mice (Figure 6) indicating the
retardation of metastases development. The presence of
mitotic cells (Figure 5D), eosinophils (Figure 5C), and
neutrophils in the sections of isRNA-treated mice indi-
cates signs of the activation of the immune response. It
should be noted that leukocytes were not observed in
the organ sections of poly(I:C)-treated mice.. Each group consisted of 7 mice.
Figure 5 Liver of CBA/LacSto mice 22 days after HCC G-29 cells inoculation showing internal and surface metastases. A. Untreated mice.
Arrows show the typical metastasis. In the blood vessel (*) painted plasma and a deformed erythrocytes can be seen. B. Large surface metastasis
in liver of poly(I:C) treated mice. C. Eosinophils (arrows) and D. mitoses (arrows) in liver of mice after isRNA injections. Paraffin sections,
hematoxylin and eosin staining.
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the number of metastases and their average size in or-
gans of isRNA-treated mice in comparison with organs
of the untreated, mock-treated, and poly(I:C)-treated
animals (Figure 6). The injections of isRNA lead to a
twofold decrease of the total area of metastases in the
kidneys and the heart, and to a threefold decrease of
metastases area in the liver (Figure 6). Notably, the in-
jections of poly(I:C) in mice caused a 15-fold increase of
metastases area in the lungs and a threefold increase in
the liver in comparison with the untreated or mock-
treated mice. In the kidneys of mock-treated mice, a
twofold increase of metastases area in comparison with
the untreated mice was observed.
Discussion
The present study shows that 19-bp RNA duplex with
3-nt overhangs at the 3′-ends of specific sequence dis-
plays immunostimulatory activities in mice with hepato-
cellular carcinoma. This isRNA is one nucleotide longer
than canonical siRNAs and has no substantial homology
with mRNAs from mice and humans, and hence this
isRNA cannot change the gene expression pattern via an
RNA interference mechanism. Analysis of immunosti-
mulatory activity of isRNA in vivo demonstrates thatisRNA strongly stimulates the synthesis of IFN-α by up
to 25-fold and only a 4.5-fold increase of IL-6 level rela-
tive to the level in Mock-treated mice (Figure 1A) after
intraperitoneal injections. Although the control type 1
interferon inducer poly(I:C) [27] activates the synthesis
of IFN-α more effectively than isRNA, it induces as high
as an 17-fold increase of IL-6 level (Figure 1B). The data
obtained are in agreement with our previous results [25]
demonstrated that isRNA after intravenous administra-
tion mainly induces the synthesis of IFNα and to a lesser
extent the synthesis of IL-6. It should be noted, that
after i.p. and i.v. administration of isRNA or poly(I:C) no
increase of tumor necrosis factor-α (TNF-α) level was
observed in mouse blood serum (data not shown). The
fact that isRNA induces the synthesis of type 1 inter-
feron but not pro-inflammatory cytokines is important
for the evaluation of the inducer as a potential adjuvant,
since the inflammatory microenvironment contributes to
the development of hepatic fibrosis, cirrhosis, carcino-
genesis, and eventually tumor metastasis [29,30]. Pro-
inflammatory cytokines TNF-α and IL-6 were found to
be the main mediators of HCC invasion [31]. Similar re-
sults were reported by other groups [26,32-34]; these
data show that 6–7 hours after injection into mice of
different types of immunostimulatory siRNA with mixed
Figure 6 Treatment of HCC G-29-bearing mice with isRNA reduces the metastases area in different organs of mice. The ratio of the total
metastases area to the total area of the organ was determined by microscopic analysis of organs sections, prepared at day 22. The data represent
means ± SEM from five microscopic fields. Statistically significant differences between experimental groups and untreated group (control) are
indicated by asterisks. **, P < 0.01; *, P < 0.05. Statistically significant differences between experimental groups and Lipofectamine-treated group
(Mock) are indicated by triangles. ▲▲, P < 0.01;▲, P < 0.05; Mann–Whitney U test. The area of metastases in the heart was evaluated using the
average length of metastases and the mean number of metastases per mm2 as described in the Methods section.
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immune response was induced, accompanied by IFN-α,
IL (interleukin)-6, and/or IFN-γ production.
In the present study, we show that isRNA applied four
times at the beginning of tumor development reliably
(P < 0.05) inhibits primary tumor growth in mice as
compared to the mock-treated group. Furthermore, in-
jections of isRNA significantly increased the intensity of
necrotic processes in the center of the primary tumor,
and decreased by twofold the width of the undifferen-
tiated peripheral zone and the number of mitotic cells in
this zone. We used the following scheme of the treat-
ment: four i.p. injections of isRNA every 3 days starting
on the 2nd day after tumor inoculation. Similar treat-
ment regimens (three systemic injections with 3-day in-
tervals) were used by two groups of authors [34,35].
Thus, our results reveal that isRNA retained the antitu-
mor properties, affecting tumor growth, but the applied
scheme of isRNA application is not sufficient for the
restriction of the tumor growth. Prolonged treatment
with isRNA and/or optimization of the scheme of mo-
notherapy is required to achieve effective suppression
of tumor growth. Probably, this preparation can display
better results as a part of combined treatment with
chemotherapy.The antimetastatic effects of isRNA were more evi-
dent. Our results demonstrate that isRNA efficiently re-
duces the metastases area in the liver, kidneys, and heart
of CBA/LacSto mice bearing HCC G-29. The incidence
of mitosis, together with the small size of metastases, in-
dicates that the metastases in isRNA-treated mice are at
an earlier stage of development than that in the control
group of mice. Infiltration of the tumor with eosinophils
and neutrophils was observed only in isRNA-treated
animals, which suggests an activated immune response.
However, despite the fact that isRNA displays immunos-
timulatory, antitumor, and antimetastatic properties, the
lifespan of isRNA-treated mice was not significantly in-
creased because of the ineffective suppression of primary
tumor growth.
It should be noted, that the injections of poly(I:C) com-
plexed with Lipofectamine, or Lipofectamine alone re-
sulted in an increase of metastases area in some organs
and a slight increase in tumor volume in comparison
with the untreated mice. Although poly(I:C)/Lipofectamine
complex effectively induces IFN-α synthesis, it also leads to
prolonged and efficient increase of pro-inflammatory cyto-
kine IL-6 level. Several studies have shown that in case of
HCC the development of inflammatory response contri-
butes to the development of cirrhosis, carcinogenesis, and
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lipid-based carrier and itself may also induce inflammation
[36], that is far less toxic than the poly(I:C)/ Lipofectamine
complexes, but they are not without overt toxicity.
It has been shown in several studies that activation of
innate immunity by the addition of RIG-I agonist triphos-
phate to the 5′-ends of oncogene-specific siRNAs [34], or
by conjugation of siRNA with CpG oligonucleotide, a po-
tent TLR9 agonist [37,38], can potentiate siRNA antitumor
effects. Antitumor activity is employing via the induction
of type I IFNs, the activation of tumor-resident macro-
phages, and the restoration of normal immune function.
In a recent study, it has been shown by Khairuddin et al.
that activation of the innate immune response by siRNAs
has significant antitumor effects against HPV-driven tu-
mors, even in the absence of a specific gene target [35].
These findings imply the potential prophylactic and thera-
peutic use of immunostimulatory siRNAs as adjuvants.
In the present study, we applied 19-bp RNA duplex with
3-nt overhangs at the 3′-ends in complex with Lipofecta-
min for the therapy of HCC G-29 bearing mice. Based on
published data, at least 4 signaling pathways may re-
cognize small RNA molecules and induce production of
type I IFNs and pro-inflammatory cytokines, including the
RIG-I/MDA5 pathway, the TLR3 pathway, the TLR7/8
pathway, and the PKR pathway. RIG1 recognizes blunt-
ended dsRNA molecules with a 5′-triphosphate that are
over 20 bp long [39], and MDA5 is activated by long
dsRNA [40]. Since our isRNA is 19 bp duplex with 3-nt
overhangs and does not contain blunt ends or triphos-
phate residues, it was supposed that it activate innate im-
munity trough RIG1/MDA5-independent pathway. The
isRNA under study may, on the one hand, activate PKR,
leading to PKR auto phosphorylation, and on the other
hand, enter the endosome by Lipofectamine and recog-
nized by TLR3, 7/8. Both the PKR activation and TLR3,
7/8 signaling will stimulate production of type I IFNs and
pro-inflammatory cytokines. Several studies have shown
that small RNAs complexed with cationic delivery vehicles
can stimulate the innate immune response by activating
TLR3 [41,42], TLR7/8 [26,32], and PKR [43,44], or by in-
volving some of these cellular sensors [45,46].
Thus, our results and results of different studies
[27,34,36,38] indicate that activation of innate immunity
by immunostimulatory nucleic acids and their analogs
possess antitumor and antimetastatic properties in tumor-
bearing mice. These properties were proved to depend on
the type I IFN signaling pathway, since anti-metastatic
properties of the drugs were significantly decreased in
mice deficient for the IFN-α/β receptor [47].
Conclusions
Our results show that 19-bp-long isRNAs with 3-nt
overhangs at the 3′-ends induce IFN-α (Figure 1), butnot proinflammatory cytokines IL-6 and TNF-α secre-
tion in CBA/LacSto mice [25]. It is very important for
HCC treatment to use type I IFN inducers, because in
many cases HCC develops on a background of chronic
inflammatory liver disease (hepatitis B and C, cirrhosis)
and secretion of pro-inflammatory cytokines could ad-
ditionally complicate the course of disease. IFN therapy,
however, significantly suppresses development of HCCs
on the background of chronic hepatitis and liver cir-
rhosis [14-16]. Our data revealed that isRNA displays ef-
ficient immunostimulatory and antimetastatic properties
in mice with HCC. Moreover, isRNA treatment leads to
a decrease in the pool of undifferentiated cells in HCC
G-29 primary tumor nodes of mice. Thus, the studied
isRNA can be considered as a potential adjuvant for the
therapy of HCC and other immunosuppressive onco-
logical diseases.
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